TENX - Tenax Therapeutics, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
1.2144
-0.0059 (-0.48%)
As of 12:08PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close1.2203
Open1.2100
Bid1.2000 x 3000
Ask1.2200 x 1400
Day's Range1.2000 - 1.2200
52 Week Range1.1000 - 2.7900
Volume12,960
Avg. Volume41,529
Market Cap8.059M
Beta (5Y Monthly)1.48
PE Ratio (TTM)N/A
EPS (TTM)-3.0370
Earnings DateMar 29, 2020 - Apr 02, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.22
  • Business Wire

    Tenax Announces the Addition of Mayo Clinic Expert, Dr. Barry Borlaug, to Scientific Advisory Board

    Tenax Therapeutics, Inc. (NASDAQ: TENX) adds Dr. Barry Borlaug of Mayo Clinic to scientific advisory board for Phase 2 levosimendan trial in PH-HFpEF

  • TENX: Enrollment Completion Expected 1Q:20
    Zacks Small Cap Research

    TENX: Enrollment Completion Expected 1Q:20

    By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Tenax Therapeutics (NASDAQ:TENX) updated investors on its Hemodynamic Evaluation of Levosimendan in Patients with PH-HFpEF (HELP) trial status last week in a January 13, 2020 release. Twenty-four patients have been randomized and an 86% initial response rate has been observed in screened patients. The average reduction in

  • Business Wire

    Tenax Therapeutics Provides Update on Phase 2 Pulmonary Hypertension Clinical Trial

    Tenax Therapeutics, Inc. (Nasdaq:TENX) provides update on Phase 2 levosimendan trial in PH-HFpEF. Project completing enrollment 1st quarter of 2020.

  • Does Tenax Therapeutics, Inc. (NASDAQ:TENX) Have A Particularly Volatile Share Price?
    Simply Wall St.

    Does Tenax Therapeutics, Inc. (NASDAQ:TENX) Have A Particularly Volatile Share Price?

    If you own shares in Tenax Therapeutics, Inc. (NASDAQ:TENX) then it's worth thinking about how it contributes to the...

  • TENX: Tenax’ HELP Update
    Zacks Small Cap Research

    TENX: Tenax’ HELP Update

    By John Vandermosten, CFA NASDAQ:TENX Tenax Therapeutics (NASDAQ:TENX) announced on October 31st that it had enrolled 15 of 36 patients in its Hemodynamic Evaluation of Levosimendan in Patients with PH-HFpEF (HELP) trial. The company also announced the average reduction in average pulmonary capillary wedge pressure (PCWP) for the successfully screened patients of 8 mmHg. As a reminder, the

  • We're A Little Worried About Tenax Therapeutics's (NASDAQ:TENX) Cash Burn Rate
    Simply Wall St.

    We're A Little Worried About Tenax Therapeutics's (NASDAQ:TENX) Cash Burn Rate

    We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

  • TENX: Focused on the Enrollment Phase
    Zacks Small Cap Research

    TENX: Focused on the Enrollment Phase

    By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Second Quarter 2019 Financial and Operational Review Tenax Therapeutics, Inc. (NASDAQ:TENX) began activating sites for its H emodynamic E valuation of L evosimendan in P atients with PH-HFpEF (HELP) trial in late 2018. After a thorough screening process, the first patient was

  • What Kind Of Investor Owns Most Of Tenax Therapeutics, Inc. (NASDAQ:TENX)?
    Simply Wall St.

    What Kind Of Investor Owns Most Of Tenax Therapeutics, Inc. (NASDAQ:TENX)?

    The big shareholder groups in Tenax Therapeutics, Inc. (NASDAQ:TENX) have power over the company. Institutions will...

  • Zacks Small Cap Research

    TENX: Screening & Enrollment Continue

    By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT First Quarter 2019 Financial and Operational Review Following the December 2018 activation of trial sites, Tenax Therapeutics, Inc. ...

  • Zacks Small Cap Research

    TENX: HELP Trial Enrollment Underway

    By John Vandermosten, CFA NASDAQ:TENX READ THE LATEST TENX RESEARCH REPORT 2018 Financial and Operational Review During 2018 Tenax Therapeutics, Inc. (NASDAQ:TENX) re-aligned the company towards the development ...

  • Introducing Tenax Therapeutics (NASDAQ:TENX), The Stock That Collapsed 98%
    Simply Wall St.

    Introducing Tenax Therapeutics (NASDAQ:TENX), The Stock That Collapsed 98%

    Tenax Therapeutics, Inc. (NASDAQ:TENX) shareholders will doubtless be very grateful to see the share price up 64% in the last quarter. But will that heal all the wounds inflicted overRead More...

  • Business Wire

    Tenax Therapeutics Enrolls First Patient for Phase 2 Pulmonary Hypertension Clinical Trial

    Tenax Therapeutics, Inc. (TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that the first patient has been randomized for the Company’s Phase 2 trial designed to evaluate levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). The study, also known as the HELP Trial (Hemodynamic Evaluation of Levosimendan in Patients with PH-HFpEF), is designed to enroll a total of 36 PH-HFpEF patients at up to approximately 10-12 major research institutions across the US. Anthony DiTonno, CEO of Tenax Therapeutics, Inc., stated, “Enrolling our first patient is an important milestone for the HELP trial.